Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 16/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL806938 | 0.87 | RYR2 (1.00) | RYR2KCNH2NOTUMKDM4E | |
| SCHEMBL7560987 | 0.83 | RYR2 (0.72) | RYR2KCNH2NOTUM | |
| SCHEMBL15936473 | 0.83 | RYR2 (0.72) | RYR2KDM4E | |
| SCHEMBL13622149 | 0.82 | RYR2 (0.71) | RYR2KCNH2 | |
| SCHEMBL6867212 | 0.81 | RYR2 (0.78) | RYR2KCNH2NOTUM | |
| SCHEMBL9635059 | 0.80 | RYR2 (0.72) | RYR2KCNH2NOTUM | |
| SCHEMBL6867029 | 0.80 | RYR2 (1.00) | RYR2KCNH2NOTUMKDM4E | |
| SCHEMBL6866477 | 0.80 | RYR2 (0.72) | RYR2KCNH2NOTUM | |
| SCHEMBL6866625 | 0.80 | RYR2 (1.00) | RYR2 | |
| SCHEMBL7555363 | 0.79 | RYR2 (0.69) | RYR2KCNH2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710045-B2 | Agents for preventing and treating disorders involving modulation of the ryanodine receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-04-29 | — | — | US | disclosed |
| US-8022058-B2 | Agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110172190-A1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYANODINE RECEPTORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172190-A1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYANODINE RECEPTORS | RYR1, RYR2, ATP2A1 | RYR2 2/4885KCNH2 215/4885NOTUM 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.